Clinical Trial Update: A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention [Phase 2]

View source ↗

Summary

A completed Phase 2 pharmacokinetic study evaluated SB-681323 in subjects with coronary artery disease undergoing percutaneous intervention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• SB-681323

Snippet

Sponsor: GlaxoSmithKline | Conditions: Coronary Heart Disease | Phase 2 | Status: COMPLETED